BortiRel (Bortezomib) for Intravenous Injection | Reliance Life Sciences - LifeSciences
- AzatiRel® (Azacitidine)
- BortiRel® (Bortezomib)
- ErlotiRel® (Erlotinib)
- ImatiRel® (Imatinib)
- Isabis® (Sodium hyaluronate)
- LeuproRel® (Leuprolide)
- ReliCitabine® (Capecitabine)
- ReliDomide® (Lenalidomide)
- ReliTrexed® (Pemetrexed)
- SynoLife™ / SynoLife One™ (Hyaluronate Injection)
- TemoRel® (Temozolomide)
- TerliRel® (Terlipressin)
Business Pharmaceuticals BortiRel
BortiRel (Bortezomib) for Injection is an antineoplastic agent available for intravenous injection (IV) or subcutaneous use (SC). Bortezomib is a modified dipeptidyl boronic acid. Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins.
BortiRel (bortezomib) for Injection is a proteasome inhibitor indicated for Multiple Myeloma part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation and for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation. BortiRel® is also indicated for Mantle Cell Lymphoma for the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least one prior therapy.
It is available in strengths: 1 mg, 2 mg and 3.5 mg.